Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study

References

• KleinmanMEBaffiJZAmbatiJThe multifactorial nature of retinal vascular diseaseOphthalmologica2010224Suppl 1162420714177
   PubMed Web of Science ®Google Scholar
• WolfensbergerTJGregorZJMacular edema – rationale for therapyDev Ophthalmol201047495820703043
   PubMedGoogle Scholar
• SaraoVVerittiDBosciaFLanzettaPIntravitreal steroids for the treatment of retinal diseasesScientific World Journal2014201498950124526927
   PubMed Web of Science ®Google Scholar
• HardmanJGLimburdLEMolinoffPBRuddonRWGilmanAGGoodman and Gilman’s: The Pharmacological Basis of Therapeutics9th edNew York, NY, USAMcGraw-Hill1996
   Google Scholar
• KwakHWD’AmicoDJEvaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injectionArch Ophthalmol19921102592661736876
   PubMed Web of Science ®Google Scholar
• MaxwellDPJrBrentBDDiamondJGWuLEffect of intravitreal dexamethasone on ocular histopathology in a rabbit model of endophthalmitisOphthalmology199198137013751945311
   PubMed Web of Science ®Google Scholar
• NabihMPeymanGATawakolMENaguibKToxicity of high-dose intravitreal dexamethasoneInt Ophthalmol1991152332351917317
   PubMed Web of Science ®Google Scholar
• Ozurdex (dexamethasone intravitreal implant 0.7 mg). [Package insert]Irvine, CA, USAAllergan, Inc2014
   Google Scholar
• HallerJADugelPWeinbergDVChouCWhitcupSMEvaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edemaRetina200929465118827732
   PubMed Web of Science ®Google Scholar
• Chang-LinJEAttarMAcheampongAAPharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implantInvest Ophthalmol Vis Sci201152808620702826
   PubMed Web of Science ®Google Scholar
• KuppermannBDBlumenkranzMSHallerJARandomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edemaArch Ophthalmol200712530931717353400
   PubMed Web of Science ®Google Scholar
• HallerJABandelloFBelfortRJrRandomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusionOphthalmology20101171134114620417567
   PubMed Web of Science ®Google Scholar
• HallerJABandelloFBelfortRJrDexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study resultsOphthalmology20111182453246021764136
   PubMed Web of Science ®Google Scholar
• LowderCBelfortRJrLightmanSDexamethasone intravitreal implant for noninfectious intermediate or posterior uveitisArch Ophthalmol201112954555321220619
   PubMed Web of Science ®Google Scholar
• BoyerDSFaberDGuptaSDexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patientsRetina20113191592321487341
   PubMed Web of Science ®Google Scholar
• ShaikhAHPetersenMRSiskRAFosterRERiemannCDMillerDMComparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusionOphthalmic Surg Lasers Imaging Retina201344283323418731
   PubMed Web of Science ®Google Scholar
• BoyerDSYoonYHBelfortRJrThree-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edemaOphthalmology20141211904191424907062
   PubMed Web of Science ®Google Scholar
• BezatisASpitalGHohnFFunctional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up – the SOLO studyActa Ophthalmol201391e340e34723638803
   PubMed Web of Science ®Google Scholar
• CaponeAJrSingerMADodwellDGEfficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (SHASTA study)Retina20143434235123846381
   PubMed Web of Science ®Google Scholar
• ShararehBGallemoreRTabanMOnishiSWallshJRecalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusionRetina2013331227123123518900
   PubMed Web of Science ®Google Scholar
• Dutra MedeirosMPostorinoMNavarroRGarcia-ArumiJMateoCCorcosteguiBDexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edemaOphthalmologica201423114114624356099
   PubMed Web of Science ®Google Scholar
• ZucchiattiILattanzioRQuerquesGIntravitreal dexamethasone implant in patients with persistent diabetic macular edemaOphthalmologica201222811712222310491
   PubMed Web of Science ®Google Scholar
• Tomkins-NetzerOTaylorSRBarATreatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitisOphthalmology20141211649165424650556
   PubMed Web of Science ®Google Scholar
• Ozurdex (dexamethasone intravitreal implant 07 mg) [Product monograph]Markham, ON, CanadaAllergan Inc2015
   Google Scholar
• HolladayJTProper method for calculating average visual acuityJ Refract Surg1997133883919268940
   PubMed Web of Science ®Google Scholar
• ZalewskiDRaczynskaDRaczynskaKFive-month observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implantMediators Inflamm2014201436414324659860
   PubMed Web of Science ®Google Scholar
• PetrashJMAging and age-related diseases of the ocular lens and vitreous bodyInvest Ophthalmol Vis Sci201354ORSF54ORSF5924335070
   PubMed Web of Science ®Google Scholar
• BhatnagarPSchiffWMBarileGRDiabetic vitrectomy: the influence of lens status upon surgical outcomesCurr Opin Ophthalmol20081924324718408501
   PubMed Web of Science ®Google Scholar
• KruhJFosterCSCorticosteroid-sparing agents: conventional systemic immunosuppressantsDev Ophthalmol201251294622517202
   PubMedGoogle Scholar